Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-express HER-2/Neu.

Next Previous
Trial Profile

Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-express HER-2/Neu.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Doxorubicin; Gemcitabine; Paclitaxel; Pegfilgrastim
  • Indications Breast cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use

Most Recent Events

  • 10 Dec 2018 Status changed from active, no longer recruiting to discontinued due to drug toxicity.
  • 23 Jan 2018 Planned End Date changed from 1 Dec 2013 to 1 Aug 2018.
  • 23 Jan 2018 Planned primary completion date changed from 1 Dec 2013 to 1 Aug 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top